-

06:57:30 PM

BPTS Stock News

BPTS - Biophytis

03/17/23 3:20 AM

Nasdaq : BPTS

low float

Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program

Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging,

RHEA-AI

neutral

03/09/23 2:20 AM

Nasdaq : BPTS

conferencesclinical triallow float

Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference

Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging,

RHEA-AI

neutral

03/02/23 2:00 AM

Nasdaq : BPTS

covid-19low float

Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19

Biophytis and Intsel Chimos signed a master service agreement under which Intsel Chimos will be the operating pharmaceutical company/exploitant, partner and distributor in France for the drug Sarconeos (BIO101) developed by Biophytis in the context of the early access program application. The

RHEA-AI

neutral

02/27/23 2:20 AM

Nasdaq : BPTS

covid-19low float

Biophytis Initiates the Regulatory Process for an Early Access Authorization in France from the French National Authority for Health (HAS) for the Treatment with Sarconeos (BIO101) of Severe Forms of COVID-19

Biophytis to present the early access application in France at a pre-filing meeting in March with the HAS Biophytis plans to file the application shortly after with the objective of obtaining early access authorization in France in the second quarter of 2023 Biophytis is pursuing in parallel the

RHEA-AI

neutral

02/23/23 2:20 AM

Nasdaq : BPTS

conferenceslow float

Biophytis To Host a Combined General Shareholder’s Meeting on March 30, 2023

Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris: ALBPS) (the "Company" or

RHEA-AI

neutral

02/02/23 2:20 AM

Nasdaq : BPTS

clinical trialcovid-19low float

Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19

RHEA-AI

neutral

01/31/23 2:20 AM

Nasdaq : BPTS

earningslow float

Biophytis Publishes its Financial Results for the First Half of 2022

Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS),

RHEA-AI

very negative

01/19/23 2:00 AM

Nasdaq : BPTS

low float

Biophytis: Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd

Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company

RHEA-AI

neutral

01/12/23 2:20 AM

Nasdaq : BPTS

low float

Biophytis To Take Appropriate Measures After Receiving Nasdaq Deficiency Notice

Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging,

RHEA-AI

neutral

01/05/23 2:20 AM

Nasdaq : BPTS

low float

Biophytis Announces Its Participation in Two Major Investor Conferences in January, In the United States and In France: The JP Morgan Healthcare Conference and The Invest Securities Biomed

Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "company") a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging,

RHEA-AI

neutral

1 2 3 4 5 6 7 Next